Patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia treated with blinatumomab have increased overall survival and a lower incidence rate of selected adverse events when compared with standard-of-care chemotherapy.

Blinatumomab treatment risks include cytokine release syndrome, neurotoxicity, and medication errors.